
Background: Community-acquired intra-abdominal infections (CA-IAIs) exhibit significant clinical heterogeneity. However, most studies focusing on CA-IAIs do not stratify comparisons by infection site. Methods: This post hoc analysis of the prospective multicenter PERICOM cohort (13 French university hospitals, April 2018 to February 2019) included adult patients with CA-IAIs requiring surgical management. We compared clinical characteristics, microbiology, and outcomes between appendicular and non-appendicular sites. Secondary analyses assessed the impact of Enterococcus spp., Pseudomonas aeruginosa, or fungal documentation, and the theoretical coverage of empirical antibiotic regimens. Results: Of the 205 patients, 86 (42%) had appendicular and 119 (58%) had non-appendicular CA-IAIs. Appendicular CA-IAIs involved younger patients with fewer comorbidities and were followed by fewer major postoperative complications (Clavien-Dindo score ≥ 3: 10% versus 43%, p < 0.001) and no deaths (0% versus 12%, p < 0.001). Among 118 culture-positive patients, appendicular CA-IAIs showed higher rates of non-fermenting Gram-negative bacilli (25% versus 10%, p = 0.046) and anaerobes (53% versus 28%, p = 0.008) and were more often polymicrobial (76% versus 55%, p = 0.020). Conversely, Staphylococcus spp. (0% versus 9%, p = 0.036) and fungal co-infection (0% versus 12%, p = 0.010) were confined to non-appendicular CA-IAIs. Furthermore, Enterococcus spp. documentation (24/118, 20%) identified patients with greater admission severity and higher 28-day mortality (33% versus 2%, p < 0.001). Amoxicillin-clavulanic acid plus gentamicin covered the isolates of 92% of patients versus 61% for third-generation cephalosporin plus metronidazole (p < 0.001), a difference identical in both appendicular and non-appendicular sites. Conclusions: Appendicular and non-appendicular CA-IAIs appear to be distinct entities, supporting stratified management. Future guidelines should consider site-specific strategies, therapeutic individualization, and the integration of CA-IAI ecology.
Muslim perceptions of cultured meat are shaped by a multifaceted interplay of religious, cultural, and ethical factors, which significantly influence consumer acceptance. A primary concern for Muslims is the halal status of cultured meat, which must comply with Islamic dietary laws.The IIFA resolution provides aniimportant recent framework for assessing the halal status of cultured meat and sets out several requirements that must be met for cultured meat to be considered premissible. However, further steps are needed, particularly at the halal certification level. Thus, this article provides a comprehensive analysis of the halal status of cultured meat within Islamic jurisprudence, assesses the readiness of current halal certification standards, and identifies the next steps required for halal certification bodies. Through an examination of recent fatwas issued by major religious bodies, we identify three key theological concerns: (1) the origin of stem cells (whether from animalsslaughtered in accordance with halal requirements or otherwise), (2) the composition of the culture medium (particularly the use of fetal bovine serum and the acceptability ofalternative media), and (3) the absence of forbidden substances, such as spilled blood, alcohol, or materials extracted from pigs. The analysis reveals a spectrum of opinions: while certain institutions have conditionally approved cultured meat pending strict oversight, others maintain a precautionary stance due to unresolved Shariah compliance issues. For cultured meat to gain widespread acceptance among Muslim consumers, it is imperative to establish standardised halal certification protocols that comprehensively address both theological principles and technical production requirements. However, without clear halal certification from trusted halal authories, many Muslims remain hesitant about cultured meat.
Discomfort of noninvasive respiratory supports remain controversial. In the present study, the discomfort of high flow nasal cannula oxygen, noninvasive ventilation, and conventional oxygen therapy were evaluated in the post-extubation period. Noninvasive ventilation alternating with high flow nasal cannula oxygen or conventional oxygen therapy were implemented for 48 h following extubation in patients free of chronic obstructive pulmonary disease. Using a 10-cm visual analog scale, the discomfort of the interface (oxygen mask, nasal prongs or facial mask), was self-evaluated by 264 patients after extubation whereas the discomfort of the respiratory support (conventional oxygen therapy or high flow nasal cannula oxygen alternating with noninvasive ventilation) was evaluated by the nurses in 306 patients. Evaluations were performed in patients at high (n = 127) and low (n = 179) risk of postextubation respiratory failure, 6, 24 and 48 h after extubation. Facial mask was the source of a significant and persisting self-evaluated discomfort. Nasal prongs and oxygen mask were less uncomfortable, with a progressive reduction of the discomfort with time. High flow nasal cannula oxygen alternating with noninvasive ventilation caused a significant and persisting nurse-reported discomfort. Conventional oxygen therapy was significantly less uncomfortable, and the degree of discomfort was not different in patients at high and low risk of extubation failure. Noninvasive ventilation was associated with a significant and persisting discomfort whereas high flow nasal cannula oxygen-induced discomfort remained limited. After 48 h, discomfort resulting from high flow nasal cannula oxygen and conventional oxygen therapy was similar and negligible.
Objective The Contemporary Prospective Understanding of Migraine Real-world Evidence (CAPTURE) study will provide 2 years of international, prospective, longitudinal data describing the migraine disease course, determinants of disease evolution, and associated treatment patterns. Methods Adults with ≥1 year migraine history who were <50 years of age at onset and currently receiving ≥1 acute and/or preventive migraine medication were enrolled at headache centers (target sample size: n = 1600). Eligible participants were required to have experienced ≥4 monthly headache days in the 3 months before screening. The study population was stratified into 3 cohorts based on monthly headache day frequency during the 1-month screening period: cohort 1: 4 to <8; cohort 2: 8 to <15; cohort 3: ≥15. We collected baseline descriptive demographic and clinical data, including treatment patterns. We will assess migraine evolution over a 24-month follow-up by measuring changes in headache frequency, acute and preventive medication use, patient-reported outcomes (migraine-related disability, quality of life, work productivity, and activity), and migraine-related health care resource utilization. Results As of November 2024, 1062 participants, who were predominantly female and from Europe, were enrolled and included in the full analysis set. Ages were similar across cohorts (mean [range] years, cohort 1: 42.3 [18–72]; cohort 2: 42.2 [18–79]; cohort 3: 43.0 [19–77]). At baseline, >50% of participants were receiving both acute and preventive migraine treatments (cohort 1: 50.0%; cohort 2: 56.4%; cohort 3: 57.6%). Approximately 25% were receiving only acute treatment at baseline (cohort 1: 26.8%; cohort 2: 24.3%; cohort 3: 23.0%), and <20% were receiving only preventive treatment at baseline (cohort 1: 17.3%; cohort 2: 14.0%; cohort 3: 12.8%). Triptans were the most frequent acute treatment at baseline for all cohorts (56.7–59.4%). CGRP mAbs were the most common preventive treatment at baseline for cohorts 1 (20.5%) and 2 (17.8%); onabotulinumtoxinA (22.4%) was the most common in cohort 3. Migraine-related quality-of-life and work productivity decreased proportionally with higher headache frequency. All cohorts reported high migraine-related disability and the presence of interictal burden, with increasing severity from cohort 1 through cohort 3. Similar trends were also observed for anxiety and depression symptoms, and patient-rated disease severity. Cohort 3 also had the lowest acute treatment optimization scores. Conclusion CAPTURE will provide greatly needed international longitudinal data assessing determinants of the evolution of migraine and its associated burden in the context of contemporary treatment patterns. These results will enhance our understanding of predictors of the course of migraine over time.